Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial
Reinhard Dummer, Jan C. Brase, James E. Garrett, Catarina D. Campbell, Eduard Gasal, Matthew Squires, Daniel Gusenleitner, Mario Santinami, Victoria Atkinson, Mario Mandalà, Vanna Chiarion‐Sileni, Keith T. Flaherty, James Larkin, Caroline Robert, Richard Kefford, John M. Kirkwood, Axel Hauschild, Dirk Schadendorf, Georgina V. Long
Topics & Concepts
DabrafenibTrametinibMedicineInternal medicineOncologyPlaceboBiomarkerClinical endpointRandomized controlled trialMelanomaCancerClinical trialAdjuvant therapyVemurafenibPathologyCancer researchMetastatic melanomaMAPK/ERK pathwayKinaseCell biologyBiologyBiochemistryChemistryAlternative medicineMelanoma and MAPK PathwaysCutaneous Melanoma Detection and ManagementCancer Immunotherapy and Biomarkers